2e5 of Human TSLP R (Luc) HEK293 Reporter Cells were stained with 100 μL of 1 μg/mL of Human TSLP Protein (R127A, R130A), His Tag (Cat. No. TSP-H5243) and negative control protein respectively, washed and then followed by PE anti-His Tag Antibody and analyzed with FACS (Routinely tested).
2e5 of Human TSLP R (Luc) HEK293 Reporter Cells were stained with 100 μL of 1 μg/mL of Human TSLP (R127A, R130A) Protein, Mouse IgG2a Fc Tag (Cat. No. TSP-H5255) and negative control protein respectively, washed and then followed by PE anti-mouse IgG2a Antibody and analyzed with FACS(Routinely tested).
Captured Human TSLP (R127A, R130A), His Tag (Cat. No. TSP-H52Ha) on CM5 Chip via anti-His antibody, can bind Human TSLP R, Fc Tag (Cat. No. TSR-H525a) with an affinity constant of 4.22 nM as determined in SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Tezepelumab | AMG-157; MEDI-9929 | Approved | Amgen Inc | Tezspire | United States | Asthma | Astrazeneca Ab | 2021-12-17 | Eosinophilic Esophagitis; Hypersensitivity; Dermatitis, Atopic; Hypersensitivity, Immediate; Bronchial Diseases; Pulmonary Disease, Chronic Obstructive; Respiratory Hypersensitivity; Sinusitis; Asthma; Granulomatosis with Polyangiitis; Lung Diseases; Immune System Diseases; Chronic Urticaria; Respiratory Tract Diseases; Nasal Polyps; Anaphylaxis; Carcinoma; Lung Diseases, Obstructive | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Bosakitug | BSI-045B; TQC-2731; TQC2731 | Phase 3 Clinical | Boaoxin Biotechnology(Nanjing) Co Ltd | Nasal Polyps; Sinusitis; Asthma; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details |
Solrikitug | MK-8226; NSI-8226 | Phase 2 Clinical | Merck & Co Inc | Hypertension; Eosinophilic Esophagitis; Asthma; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details |
Ecleralimab | CSJ-117; NOV-14 | Phase 2 Clinical | Novartis Pharma Ag | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
WIN-1001X | WIN-1001X | Phase 2 Clinical | Whanin Pharmaceutical Co Ltd | Nerve Degeneration; Parkinson Disease | Details |
PF-07275315 | PF-07275315 | Phase 2 Clinical | Pfizer Inc | Dermatitis, Atopic | Details |
Lunsekimig | SAR-443765 | Phase 2 Clinical | Sanofi | Nasal Polyps; Asthma; Sinusitis; Inflammation; Dermatitis, Atopic | Details |
AZD-8630 | AZD-8630; AMG-104 | Phase 2 Clinical | Astrazeneca Plc, Amgen Inc | Asthma | Details |
TAVO-101 | TAVO-101; TAVO101 | Phase 2 Clinical | Tavotek Biotherapeutics (Hong Kong) Ltd | Dermatitis, Atopic; Hypersensitivity | Details |
SHR-1905 | SHR-1905; AIO-001; GSK-5784283 | Phase 2 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Nasal Polyps; Respiratory Tract Diseases; Sinusitis; Asthma; Pulmonary Disease, Chronic Obstructive | Details |
CM-326(Connaught Biomedical Technology) | CM326; CM-326 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Nasal Polyps; Sinusitis; Asthma; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details |
PF-06342674 | RN-168; PF-6342674; PF-06342674; ZB-168 | Phase 1 Clinical | Pfizer Inc | Diabetes Mellitus, Type 1; Multiple Sclerosis | Details |
HBM-9378 | HBM-9378; SKB378; SKB-378; A-378; WIN378; WIN-378 | Phase 1 Clinical | Harbour Biomed, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
HB-0056 | HB-0056; HB0056 | Phase 1 Clinical | Shanghai Huaota Biopharmaceutical Co Ltd | Asthma | Details |
APG-333 | APG333; APG-333; PR018; PR-018 | Phase 1 Clinical | Apogee Therapeutics Inc | Asthma | Details |
SAR-444765 | SAR444765; SAR-444765 | Phase 1 Clinical | Sanofi | Inflammation | Details |
CM-512 | CM512; CM-512 | Phase 1 Clinical | Keymed Biosciences Co Ltd | Nasal Polyps; Asthma; Sinusitis; Pulmonary Disease, Chronic Obstructive; Dermatitis, Atopic | Details |
IBI-3002 | IBI3002; IBI-3002 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Asthma | Details |
GB-0895 | GB-0895 | Phase 1 Clinical | Generate Biomedicines Inc | Immune System Diseases; Asthma | Details |
CDX-622 | CDX-622 | Phase 1 Clinical | Celldex Therapeutics Inc | Fibrosis; Inflammation; Hypersensitivity | Details |
STSA-1201 | STSA-1201; STSA1201 | Phase 1 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Asthma | Details |
LQ043H | LQ043H | Phase 1 Clinical | Shanghai Novamab Biopharmaceuticals Co Ltd | Asthma | Details |
GR2002 | GR2002 | Phase 1 Clinical | Genrix (Shanghai) Biopharmaceutical Co Ltd | Nasal Polyps; Asthma; Sinusitis; Dermatitis, Atopic | Details |
QX-008N | QX008N; QX-008N | Phase 1 Clinical | Qyuns Therapeutics Co Ltd | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
This web search service is supported by Google Inc.